NCT01782976 2018-01-19Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)M.D. Anderson Cancer CenterPhase 2 Withdrawn
NCT01517776 2015-07-21HGG-CilMetroMartin-Luther-Universität Halle-WittenbergPhase 2 Terminated28 enrolled
NCT00705016 2014-04-30ADVANTAGEMerck KGaA, Darmstadt, GermanyPhase 1/2 Completed184 enrolled 20 charts